Entering text into the input field will update the search result below

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q4 2019 Results - Earnings Call Transcript

Mar. 05, 2020 11:13 AM ETArbutus Biopharma Corporation (ABUS)1 Comment
SA Transcripts profile picture
SA Transcripts

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2019 Earnings Conference Call March 5, 2020 8:45 AM ET

Company Participants

Pam Murphy - IR

Bill Collier - President and CEO

Dave Hastings - CFO

Gaston Picchio - Chief Development Officer

Mike Sofia - Chief Scientific Officer

Conference Call Participants

Mayank Mamtani - B. Riley

Keay Nakae - Chardan

Madhu Kumar - Robert W. Baird


Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation Fourth Quarter and Year-End 2019 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]

I would now like to hand the conference over to your speaker, Ms. Pam Murphy. Please go ahead.

Pam Murphy

Good morning. On the call from the Arbutus executives team are: Bill Collier, President and Chief Executive Officer; Dave Hastings, Chief Financial Officer; Dr. Gaston Picchio, Chief Development Officer; and Dr. Mike Sofia, Chief Scientific Officer. Bill will begin with a review of corporate objectives and clinical development, followed by Dave Hastings, who'll provide a summary of the company's fourth quarter and year-end financial results. We'll then open up the call for Q&A. Mike and Gaston will be available to address research, and clinical development-related questions.

Before we begin, we'd like to remind you that some of the statements made during this call today are forward-looking statements, including statements regarding expectations for Arbutus' proprietary HBV pipeline, including potential clinical results and timelines for AB-729 and AB-836, and future compounds. Our 2020 objectives, our expected cash used and cash runway and the potential for our drug candidates to improve upon standard of care and contribute to a curative combination regimen for HBV. These forward-looking statements are subject

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.